Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

http://www.wikidata.org/entity/Q48351188

about

Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases From single target to multitarget/network therapeutics in Alzheimer's therapy In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity.AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease.Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces.Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations.Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer's Disease.Benefits and risks of add-on therapies for Alzheimer's disease.Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation.Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells.Differentiation renders susceptibility to excitotoxicity in HT22 neurons Tacrine, Trolox and Tryptoline as Lead Compounds for the Design and Synthesis of Multi-target Agents for Alzheimer's Disease Therapy.Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment.Docking-based design and synthesis of galantamine-camphane hybrids as inhibitors of acetylcholinesterase.The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon.Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database.Galantamine Derivatives as Acetylcholinesterase Inhibitors: Docking, Design, Synthesis, and Inhibitory Activity Docking-based Design of Galantamine Derivatives with Dual-site Binding to Acetylcholinesterase

P2860

Q26748936-7C6CEBCD-3DE3-450C-810F-BB05A1E58750 Q28066691-FAB0AED5-6124-4876-AE50-F1C632936475 Q28658200-A5626E9A-C88F-41AB-BD6B-CE02D6D10B25 Q28830911-C8AD8BE7-4696-4949-A79B-38A19B93C6ED Q33905343-6887913F-BA03-4581-83CF-1E76380D6B89 Q35617556-0369F156-454D-4933-80CA-7BE3A1334E64 Q36713096-B0665951-F4FC-40BC-921D-0CBB09974759 Q36925910-8B31A98E-FB92-42E9-A5A3-62C518E7068D Q38099671-FD5178F2-22EB-4FBE-8AA6-4FF9CFB86CD9 Q38184970-D7C95DED-77A8-43A2-8467-62BDD7E247E4 Q38209550-8A2E26B9-70B5-453A-9669-B7CC3870662C Q38213710-5328F441-9235-435B-980A-A16FF6D199A9 Q38620338-AB551F9A-EBB9-4794-8FAE-940FED88CBE7 Q38668998-46CFE713-F4FC-4E0B-BC57-C07593BD8279 Q38881147-01AF016A-E1A5-4573-82F9-EF79CABCBB25 Q39013934-855450DE-B6A2-4E19-B5C8-DDFC36B1E0F6 Q39153827-23710FE2-8AD0-4969-BE53-48609CC62B95 Q42289492-103CC667-7718-464D-91B2-278925359AAA Q42293352-FF011365-702C-4A2B-B81B-BBB486884ED4 Q48231536-D01DCD4C-DAA8-47BD-A1FE-339F12CA074B Q50859830-A3FFC6CE-39F0-4456-BF97-61B3CB58FFA5 Q52590455-4AE206AC-873D-4337-8E0A-8CA7ABA7E09B Q57021427-40C81828-6371-45CF-B0E4-42BE56E7B2E5 Q57021449-29326D9D-7BC2-4F9B-9C25-35E8873E7434

P2860

Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

http://www.wikidata.org/entity/Q48351188

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Combining galantamine and mema ...... useful in Alzheimer's disease.

@en

Combining galantamine and mema ...... useful in Alzheimer's disease.

@nl

type

label

Combining galantamine and mema ...... useful in Alzheimer's disease.

@en

Combining galantamine and mema ...... useful in Alzheimer's disease.

@nl

altLabel

Combining Galantamine and Mema ...... Useful in Alzheimer’s Disease

@en

prefLabel

Combining galantamine and mema ...... useful in Alzheimer's disease.

@en

Combining galantamine and mema ...... useful in Alzheimer's disease.

@nl

P1433

Q48351188-437A46C9-E42D-4E9B-B293-A2BC98CFBBE2

P1476

Q48351188-E861AC50-3E69-49DE-96A8-15A1C5CE20B8

P2093

Q48351188-076EE89E-90B3-4EE9-A65A-277DBBF6519D

Q48351188-237A7DC4-6E5C-4C8D-9869-33D06BDF2A84

Q48351188-3E52F63D-B5DD-4F78-80DC-9277BD617EFB

Q48351188-5BCCD3B2-E39F-4692-9839-FDB2BF814D60

Q48351188-BF6AF405-D7DD-4DE8-8256-10CA73B0310A

Q48351188-C0D30796-4509-4160-BCFA-B4CEE9C1369D

Q48351188-EB4767CF-9F14-4280-8D8A-C41D35966768

Q48351188-F7160E33-3E51-4A0D-94D9-60958395C264

Q48351188-F71C69CF-C87B-4CF4-966D-9F863CDC9828

Q48351188-F8CD93A4-5C39-4998-9F2E-10B5F5137C67

P304

Q48351188-3C2FFC73-DA88-4FA3-A58E-8723D3F0ACB1

P31

Q48351188-023426E3-4609-45CE-A185-B065A877F868

P356

Q48351188-FB0EE924-E564-4D9E-8694-47C3BAABEB1E

P407

Q48351188-DBC54C08-F972-4DB6-8F68-B50FDBF7D635

P433

Q48351188-C46B1124-352A-41FD-9CF5-08F70658BDBA

P478

Q48351188-B1E64F42-E86D-4CF1-98F1-8F25A8D4009C

P50

Q48351188-B88C9C5D-83DA-4791-AFE6-CC4315751A3F

Q48351188-E791BBE4-DD08-4414-9282-E3F45901DC49

Q48351188-FD95E63F-50FA-4CC1-BCB3-CA9CA71B8FB5

P577

Q48351188-C7E1B7B9-F9B0-4465-A277-16D6821F6E77

P698

Q48351188-9758A7A1-C6EE-4517-873B-BB87051E1AD8

P921

Q48351188-0F726316-76DC-4B2F-87D1-D353BA97A3D6

P356

P1433

Journal of Medicinal Chemistry

P1476

Combining galantamine and mema ...... useful in Alzheimer's disease.

@en

P2093

Andrea Cavalli

http://www.w3.org/2001/XMLSchema#string

Angelo Reggiani

http://www.w3.org/2001/XMLSchema#string

Carlo Melchiorre

http://www.w3.org/2001/XMLSchema#string

Daniela Pizzirani

http://www.w3.org/2001/XMLSchema#string

Daniele Piomelli

http://www.w3.org/2001/XMLSchema#string

Elena Simoni

http://www.w3.org/2001/XMLSchema#string

Glauco Tarozzo

http://www.w3.org/2001/XMLSchema#string

Luca Goldoni

http://www.w3.org/2001/XMLSchema#string

Michela Rosini

http://www.w3.org/2001/XMLSchema#string

Simona Daniele

http://www.w3.org/2001/XMLSchema#string

P304

9708-9721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM3009458

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Maria Letizia Trincavelli

Claudia Martini

Giovanni Bottegoni

P577

2012-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23033965

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease